Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
11:55am, Tuesday, 26'th Nov 2024
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
09:03am, Monday, 25'th Nov 2024
On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardio
BridgeBio: Next Chapter Begins After Attruby Approval
03:48pm, Sunday, 24'th Nov 2024
BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also t
US FDA approves BridgeBio's drug for rare heart condition
07:25pm, Friday, 22'nd Nov 2024
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thy
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
02:44pm, Tuesday, 19'th Nov 2024
On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Session
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Morta
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
10:41am, Thursday, 14'th Nov 2024
BridgeBio Pharma, Inc.'s acoramidis is awaiting FDA's approval decision for transthyretin amyloidosis, with strong clinical data suggesting a likely approval and potential “blockbuster” status. Th
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
09:45am, Tuesday, 12'th Nov 2024
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.08 per share a year ago.
- Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder and MIT professor, Andrew W. Lo, Ph.D.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:06am, Thursday, 31'st Oct 2024
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the
3 Top Stocks That Could Still Rocket Higher in 2024
05:17am, Friday, 04'th Oct 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic disea
